Lilly Insulin Glargine Versus Lantus^® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study.

ABSTRACT:

Background and objectives

Lilly insulin glargine (LY IGlar; Basaglar^®) and the reference insulin glargine product (IGlar; Lantus^®) are basal insulin glargine analogs with identical amino acid sequence and similar pharmacological profiles. ELEMENT 5, a Phase 3, prospective, randomized, multinational, two-arm, active-controlled, open-label, parallel-design study in type 2 diabetes mellitus (T2DM) patients (N = 493) showed similar efficacy and safety profiles with LY IGlar and IGlar. This study reports results from India (N = 100) and East Asia (N = 134) subpopulations.

Methods

Patients from India and East Asia (Korea and Taiwan) with T2DM who were insulin naïve (glycated hemoglobin (HbA1c) ≥ 7.0% and ≤ 11.0%) or on basal insulin (HbA1c ≤ 11.0%) were rando

SUBMITTER: Mohan V 

PROVIDER: S-EPMC6656918 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature